Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019
The Food and Drug Administration approved tafenoquine for prophylaxis of malaria and antirelapse therapy.
Publication date: Available online 27 January 2020Source: Preventive MedicineAuthor(s): Nilofer S. Azad, Ira L. Leeds, Waruguru Wanjau, Eun J. Shin, William V. PadulaAbstractThe incidence of colorectal cancer (CRC) is increasing in patients under the age of 50. The purpose of this study was to assess the cost-utility of available screening modalities starting at 40 years in the general population compared to standard screening at 50 years old. A decision tree modeling average-risk of the CRC in the United States population was constructed for the cost per quality-adjusted life year (QALY) of the five most common and ef...
[Abstract unavailable] Language: en...
ConclusionWhile previous studies have suggested that super-utilizers are a homogenous group of patients, the current study demonstrated a large degree of heterogeneity within super-utilizers. Variations in utilization patterns were associated with postoperative outcomes and subsequent health care costs.
A meta-analysis of eight studies has found that previous estimates of preventable hospital deaths in the United States may be as much as four times too high.
As China agrees to permit expert teams into the country, the U.S. plans to begin evaluating arriving passengers for the infection at 20 ports of entry.
The flight will leave Wuhan, then to Alaska for refueling and land in California.
Once key destinations for Chinese tourists, Asian countries are seeking to limit flows of visitors.
Pneumococcal conjugate vaccine use in children has led to sharp declines in pneumococcal disease among adults and children.
Abstract Since the middle of the 20th century, vaccines have made a significant public health impact controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents with complex life cycles and antigenic variation remains a key challenge. Novel strategies to characterize the short and long-term immune responses to vaccines, and to induce immune responses that mimic natural infection have recently emerged. New technologies and ...